![](https://ml.globenewswire.com/media/0c6a88e8-09d4-4304-9fa5-7caa195ccac0/small/ihl-logo-png.png)
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug ...
IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alone. bioavailability/bioequivalence (‘BA/BE’) …